0000000000930678

AUTHOR

Jaqueline Heinz

showing 2 related works from this author

Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Mali…

2021

Immune checkpoint inhibitors (ICI) significantly improved the prognosis of advanced melanoma patients. However, many patients do not derive long-term benefit from ICI therapy due to primary and acquired resistance. In this regard, it has been shown that coagulation factors contribute to cancer immune evasion and might therefore promote resistance to ICI. In particular, recent observations in murine systems demonstrated that myeloid-derived factor Xa (FXa) impedes anti-tumor immunity in the tumor microenvironment and that the oral FXa inhibitor (FXa-i) rivaroxaban synergizes with ICI. The synergistic effect of FXa inhibitors with clinical ICI therapy is unknown. We performed a retrospective …

Oncologyadvanced melanomaCancer Researchmedicine.medical_specialtymedicine.drug_mechanism_of_actionmedicine.medical_treatmentFactor Xa Inhibitorfactor Xa inhibitorsanti-tumor immunityArticleimmune checkpoint inhibitorsInternal medicinemedicineProgression-free survivalanticoagulationRC254-282thromboembolic eventsRivaroxabanbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancerRetrospective cohort studyImmunotherapymedicine.diseaseOncologyConcomitantimmunotherapythromboprophylaxisbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugCohort studyCancers
researchProduct

Merkel cell carcinoma‐derived Erysipelas carcinomatosum

2019

medicine.medical_specialtySkin NeoplasmsMerkel cell carcinomabusiness.industryDermatologyGeneral Medicinemedicine.diseaseDermatologyErysipelasCarcinoma Merkel CellErysipelasmedicineHumansbusinessDermatologic Therapy
researchProduct